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1018 Modern surgical treatment of massive pulmonary embolism: Results in 47
consecutive patients after rapid diagnosis and aggressive surgical approach
Marzia Leacche, MD, Daniel Unic, MD, Samuel Z. Goldhaber, MD, James D. Rawn, MD,
Sary F. Aranki, MD, Gregory S. Couper, MD, Tomislav Mihaljevic, MD, Robert J. Rizzo, MD,
Lawrence H. Cohn, MD, Lishan Aklog, MD, and John G. Byrne, MD, Boston, Mass, and New
York, NY
We advocate aggressive surgical pulmonary embolectomy not only for hemodynamically
compromised patients or those for whom thrombolytic treatment is contraindicated but also for
hemodynamically stable patients who have a large central clot burden and right ventricular
dysfunction documented by means of echocardiography.
1024 Is early anticoagulation with warfarin necessary after bioprosthetic aortic
valve replacement?
T. M. Sundt, MD, K. J. Zehr, MD, J. A. Dearani, MD, R. C. Daly, MD, C. J. Mullany, MBMS,
C. G. A. McGregor, MD, F. J. Puga, MD, T. A. Orszulak, MD, and H. V. Schaff, MD,
Rochester, Minn
Current guidelines recommend early heparin followed by warfarin for 3 months after
bioprosthetic AVR. A retrospective analysis of patients who were (624) or were not (527)
anticoagulated demonstrated no difference in stroke. By multivariable analysis, warfarin did not
protect against stroke. The role for early anticoagulation remains undefined.
1032 Impact of preoperative and postoperative atrial fibrillation on outcome after
mitral valvuloplasty for nonischemic mitral regurgitation
Ko Bando, MD, Hitoshi Kasegawa, MD, Yukikatsu Okada, MD, Junjiro Kobayashi, MD,
Akiko Kada, MPH, Tomoki Shimokawa, MD, Michinori Nasu, MD, Satoshi Nakatani, MD,
Kazuo Niwaya, MD, Osamu Tagusari, MD, Hiroyuki Nakajima, MD, Mitsuhiro Hirata, MD,
Toshikatsu Yagihara, MD, and Soichiro Kitamura, MD, Osaka, Kobe, Tokyo, and Kanagawa,
Japan
The impact of preoperative and postoperative AF on survival, stroke, and cardiac function after
mitral valve repair for mitral regurgitation was determined in 1026 patients. Preoperative AF
was associated with reduced survival and freedom from late stroke after surgery. The addition
of a maze procedure improved late cardiac function, survival, and freedom from late stroke.
1041 Which biologic valve should we select for the 45- to 65-year-old age group
requiring aortic valve replacement?
F. Dagenais, MD, P. Cartier, MD, P. Voisine, MD, D. Desaulniers, MD, J. Perron, MD,
R. Baillot, MD, G. Raymond, MD, J. Métras, MD, D. Doyle, MD, and P. Mathieu, MD,
Quebec City, Quebec, Canada
Results with use of biologic valves (n  332) for aortic valve replacement in the 45- to 65-
year-old patient were compared. At 7 years, cardiac survival and valve complications were
comparable for the Freestyle, homograft, stented xenograft, and Ross procedure groups. Until
longer follow-up determines durability, biologic valve selection for the 45- to 65-year-old
patient should be based on patient-surgeon preference and ease of implantation and reoperation.
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